DRL greening operations: Net Zero target by FY2045 (SBTi approved), 78% renewable power in FY26, and all primary boilers are now coal-free.

Scope 3 emissions reduced by 7.7%. The company launched a generic semaglutide in India and invested ₹111.41 Cr in CSR, impacting over 1.1 million people.

No major regulatory fines reported.